Compare LWLG & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWLG | IVA |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | France |
| Employees | 34 | 77 |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 995.4M | 1.1B |
| IPO Year | 2011 | N/A |
| Metric | LWLG | IVA |
|---|---|---|
| Price | $6.51 | $4.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $16.20 |
| AVG Volume (30 Days) | ★ 3.0M | 1.2M |
| Earning Date | 05-08-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $236,855.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $751.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 147.74 | N/A |
| 52 Week Low | $1.99 | $3.16 |
| 52 Week High | $18.71 | $7.98 |
| Indicator | LWLG | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.70 | 51.00 |
| Support Level | $6.15 | $3.88 |
| Resistance Level | $7.39 | $4.70 |
| Average True Range (ATR) | 0.50 | 0.22 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 48.07 | 30.44 |
Lightwave Logic Inc is a specialty materials and intellectual property company focused on the development and commercialization of proprietary electro-optic (EO) polymer materials designed to enable high-speed optical modulators for data communications and other photonic applications. Its Perkinamine family of EO polymers is designed for integration into silicon photonics (SiPh) and other photonic integrated circuit (PIC) platforms, supporting high-speed optical modulation with lower drive voltage requirements compared with some conventional silicon-based and III-V compound semiconductor approaches. The company operates as a single reportable segment.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.